Point-of-care cervical cancer screening using deep learning-based microholography.
Cervical cancer
deep learning
global oncology
microholography
point-of-care screening
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2019
2019
Historique:
received:
31
05
2019
accepted:
24
09
2019
entrez:
28
12
2019
pubmed:
28
12
2019
medline:
15
9
2020
Statut:
epublish
Résumé
Most deaths (80%) from cervical cancer occur in regions lacking adequate screening infrastructures or ready access to them. In contrast, most developed countries now embrace human papillomavirus (HPV) analyses as standalone screening; this transition threatens to further widen the resource gap.
Identifiants
pubmed: 31879529
doi: 10.7150/thno.37187
pii: thnov09p8438
pmc: PMC6924258
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8438-8447Subventions
Organisme : NCI NIH HHS
ID : R01 CA229777
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA201248
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA201248
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA202637
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233360
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Int J Cancer. 2004 Aug 20;111(2):278-85
pubmed: 15197783
N Engl J Med. 2009 Apr 2;360(14):1385-94
pubmed: 19339719
Chem Commun (Camb). 2017 Feb 9;53(13):2134-2137
pubmed: 28134385
J Virol. 2015 Oct;89(20):10680-7
pubmed: 26269181
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):16889-94
pubmed: 21969539
Int J Gynaecol Obstet. 2005 Jan;88(1):25-30
pubmed: 15617701
Lancet Oncol. 2013 Apr;14(4):e152-7
pubmed: 23561746
Biotechnol J. 2011 Feb;6(2):138-49
pubmed: 21298800
ACS Nano. 2018 Sep 25;12(9):9081-9090
pubmed: 30113824
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11301-5
pubmed: 11572982
Theranostics. 2019 May 31;9(13):3723-3731
pubmed: 31281509
J Cancer Res Ther. 2011 Oct-Dec;7(4):454-8
pubmed: 22269409
Lab Chip. 2016 Apr 21;16(8):1340-5
pubmed: 26980325
Nat Methods. 2012 Sep;9(9):889-95
pubmed: 22936170
Proc Natl Acad Sci U S A. 2015 May 5;112(18):5613-8
pubmed: 25870273
JAMA. 2018 Jul 3;320(1):43-52
pubmed: 29971397
Theranostics. 2015 Apr 17;5(8):796-804
pubmed: 26000053
N Engl J Med. 2005 Nov 17;353(20):2158-68
pubmed: 16291985
Lancet Oncol. 2018 Dec;19(12):1569-1578
pubmed: 30392810
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Theranostics. 2017 Jun 1;7(8):2220-2230
pubmed: 28740546
Nat Biomed Eng. 2018 Sep;2(9):666-674
pubmed: 30555750
Theranostics. 2019 Apr 13;9(9):2637-2645
pubmed: 31131058
Sci Rep. 2014 Apr 16;4:4704
pubmed: 24736475
Theranostics. 2016 Jun 18;6(10):1603-10
pubmed: 27446494
Sci Transl Med. 2014 Dec 17;6(267):267ra175
pubmed: 25520396
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884